Abstract
Alzheimers disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimers disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimers disease and is approved by the US Food and Drug Administration for Alzheimers disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimers disease.
Keywords: Alzheimer's disease, cholinesterases, cholinesterase inhibitors
Current Enzyme Inhibition
Title: Cholinesterases and Cholinesterase Inhibitors
Volume: 4 Issue: 4
Author(s): Sarka Stepankova and Karel Komers
Affiliation:
Keywords: Alzheimer's disease, cholinesterases, cholinesterase inhibitors
Abstract: Alzheimers disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimers disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimers disease and is approved by the US Food and Drug Administration for Alzheimers disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimers disease.
Export Options
About this article
Cite this article as:
Stepankova Sarka and Komers Karel, Cholinesterases and Cholinesterase Inhibitors, Current Enzyme Inhibition 2008; 4 (4) . https://dx.doi.org/10.2174/157340808786733631
DOI https://dx.doi.org/10.2174/157340808786733631 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing
on Neurological Disorders
Venoms and Toxins The Versatile Stress Protein Mortalin as a Chaperone Therapeutic Agent
Protein & Peptide Letters Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy The Role of Microglial Cells on Neuroinflammation: Possible Therapeutic Applications
Recent Patents on Regenerative Medicine The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Antioxidant Protective Effects of Mushroom Metabolites
Current Topics in Medicinal Chemistry Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury
Current Medicinal Chemistry Utilizing Ultrasound to Transiently Increase Blood-Brain Barrier Permeability, Modulate of the Tight Junction Proteins, and Alter Cytoskeletal Structure
Current Neurovascular Research Nitric Oxide Induced Damage and Preventive Effect of Curcumin and Quercetin on Buffalo Brain Cystatin
Current Proteomics Nucleic Acid Therapeutics in Huntington’s Disease
Recent Patents on Biotechnology Study of the cis-trans Isomerization of the Amino-Acyl prolyl Peptide Bond. Application to the Design of Novel Inhibitors of Immunophilins
Current Organic Chemistry Pursuing Chemical Efficiency by Using Supported Organocatalysts for Asymmetric Reactions under Aqueous Conditions
Current Organocatalysis RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease
Current Molecular Medicine Nanoparticle-Based Therapy in Genomics
Current Drug Metabolism In Silico Design, Synthesis of Hybrid Combinations: Quercetin Based MAO Inhibitors with Antioxidant Potential
Current Topics in Medicinal Chemistry Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
CNS & Neurological Disorders - Drug Targets Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine Role of Autophagy in Parkinson’s Disease
Current Medicinal Chemistry Piper sarmentosum Roxb. Root Extracts Confer Neuroprotection by Attenuating Beta Amyloid-Induced Pro-Inflammatory Cytokines Released from Microglial Cells
Current Alzheimer Research